The Biotech CEO Sisterhood operates on a counterintuitive principle: eliminate competition among members. The goal is to collectively maximize company success and patient impact by freely sharing resources, advice, and lessons learned—even on sensitive topics like gracefully shutting down a company.
Instead of creating another 'more durable' version of existing drugs, Iolyx Therapeutics was founded to address the immunological roots of many eye diseases. CEO Elizabeth Jeffords notes that while conditions like Sjogren's are known to be autoimmune, treatments often fail to target the underlying immune process locally within the eye.
Elizabeth Jeffords shares a Genentech adage for biotech growth: give away your first and possibly second product via licensing deals. This strategy, which Iolyx followed, provides crucial non-dilutive capital and validation, building a foundation to eventually commercialize a third asset independently.
CEO Elizabeth Jeffords argues ophthalmology lags behind oncology in treatment philosophy. She applies oncology's core lessons—treat early, use combinations, target precisely, and act locally—to Iolyx's development strategy for immune-driven eye diseases, moving beyond one-size-fits-all approaches.
Iolyx CEO Elizabeth Jeffords insists on commercial input even in preclinical stages. This meant killing an ointment formulation—which patients find 'greasy' and 'disgusting'—in favor of developing a more patient-friendly eyedrop. This avoids creating a product that is clinically sound but has poor real-world adoption.
Iolyx Therapeutics' CEO notes the surprising capital efficiency of lean biotech. Her team advanced a drug from discovery through Phase 2 for approximately $20 million—an amount she could have easily spent on a single marketing campaign at Genentech. This highlights the operational leverage of focused, small teams.